AMICUS AI
Citation Codes
Equivalent Citations
citation codes
Case Number
Attorney(S)
Judges
Acts
  • Section 28 of The Trademarks Act, 1999 (hereinafter referred to as the said Act)
  • Order 39 Rules 1 & 2, CPC
Are you a practicing lawyer?
Enhance your digital presence and reach by creating a Casemine profile.
Upload pleading to use the new AI search
Cites
Cited by
Citation Codes
Equivalent Citations
citation codes
Case Number
Attorney(S)
Judges
Acts
  • Section 28 of The Trademarks Act, 1999 (hereinafter referred to as the said Act)
  • Order 39 Rules 1 & 2, CPC
Smart Summary

Factual and Procedural Background

The plaintiff is the registered proprietor of the trademark “ZEVIT” for pharmaceutical and related products, originally registered in 1986 and assigned to the plaintiff in 1998. The plaintiff alleges that the defendant has been manufacturing and marketing vitamin capsules under the trademark “EVIT,” which is deceptively similar to the plaintiff's mark. The plaintiff filed a suit seeking an interim injunction restraining the defendant from using the mark “EVIT.” An ex parte ad interim injunction was granted on 13.02.2003, which has continued pending further orders. The plaintiff seeks confirmation of this injunction, while the defendant seeks its vacation.

Legal Issues Presented

  1. Whether the plaintiff is entitled to an interim injunction restraining the defendant from using the mark “EVIT” in respect of pharmaceutical products.
  2. Whether the defendant's trademark “EVIT” is deceptively similar to the plaintiff's registered trademark “ZEVIT” within the meaning of Section 29 of The Trademarks Act, 1999.
  3. The extent to which the suffix “VIT,” common in vitamin formulations, affects the comparison of the trademarks.
  4. The applicability of the principles of deceptive similarity as laid down by the Supreme Court in the cited precedents to the facts of this case.

Arguments of the Parties

Plaintiff's Arguments

  • The plaintiff is the registered proprietor of the trademark “ZEVIT,” which is an invented word with no dictionary meaning and thus highly distinctive.
  • The plaintiff has continuously and regularly used the trademark “ZEVIT” for pharmaceutical vitamin formulations over many years.
  • The defendant's use of the mark “EVIT” is deceptively similar to “ZEVIT,” causing infringement under Section 29 of The Trademarks Act, 1999.
  • Registration of the trademark provides exclusive rights and prima facie evidence of validity under Sections 28 and 31 of the Act.
  • The plaintiff relies on several Supreme Court decisions affirming the proprietor's exclusive rights and the test for deceptive similarity.

Defendant's Arguments

  • The defendant's mark “EVIT” denotes a generic vitamin “E” preparation, with “VIT” being a common suffix in the pharmaceutical trade indicating vitamin formulations.
  • “VIT” is generic and should be disregarded in the comparison; only the prefixes “ZE” (plaintiff) and “E” (defendant) need comparison.
  • The prefixes “ZE” and “E” are dissimilar, thus the marks are not deceptively similar.
  • Relies on the Supreme Court decision in F. Hoffimann-La Roche and Co. Ltd. v. Geoffrey Manners and Co. Pvt. Ltd. where the Court held that common descriptive suffixes can be disregarded and only the distinctive parts compared.

Table of Precedents Cited

Precedent Rule or Principle Cited For Application by the Court
National Bell Co. v. Metal Goods Manufacturing Co. (P.) Ltd & Anr., AIR 1971 SC 898 Recognition of exclusive rights arising from trademark registration under Section 28. Supported the principle that registration grants valuable and exclusive rights to the proprietor.
American Home Products Corporation v. Mac Laboratories Pvt. Ltd & Anr., AIR 1986 SC 137 Trademark infringement test and rights of registered proprietors. Reinforced the plaintiff's entitlement to relief for infringement of a registered trademark.
Durga Dutt Sharma v. N.P Laboratories, AIR 1965 SC 980 Principles governing trademark infringement and deceptive similarity. Provided background on the legal standards applicable to trademark infringement claims.
Avis International Ltd v. Avi Footwear Industries & Anr., AIR 1991 Delhi 22 Trademark infringement and deceptive similarity analysis. Supported the plaintiff's position on the importance of exclusive rights of registered trademarks.
F. Hoffimann-La Roche and Co. Ltd. v. Geoffrey Manners and Co. Pvt. Ltd., AIR 1970 SC 2062 Test for deceptive similarity focusing on comparing marks as wholes and giving weight to uncommon elements. Defendant relied on this precedent to argue that the common suffix “VIT” is generic and should be disregarded; the court applied the principles but found the marks still deceptively similar.

Court's Reasoning and Analysis

The court acknowledged the plaintiff's registered trademark “ZEVIT” and the defendant's unregistered use of “EVIT.” It recognized that registration confers exclusive rights under Section 28 and that infringement is established if the marks are identical or deceptively similar under Section 29.

The defendant contended that the suffix “VIT” is generic and common in the pharmaceutical trade, and thus only the prefixes “ZE” and “E” should be compared. Relying on the Supreme Court decision in F. Hoffimann-La Roche, the defendant argued that the marks are dissimilar.

The court analyzed the marks as wholes and found that the prefixes “ZE” and “E” are phonetically quite similar, and the suffix “VIT” is identical. Since the marks share an identical suffix and similar prefixes, the court concluded the defendant's mark “EVIT” is deceptively similar to the plaintiff's registered trademark “ZEVIT.”

The court found that the plaintiff had established a prima facie case and that the balance of convenience favored the plaintiff. The plea of delay by the defendants was not considered significant in this infringement action.

Holding and Implications

The ex parte ad interim injunction dated 13.02.2003 restraining the defendant from using the mark “EVIT” is confirmed until the disposal of the suit.

This decision upholds the plaintiff's exclusive rights in the registered trademark “ZEVIT” and prevents the defendant from using a deceptively similar mark pending final adjudication. No new legal precedent is set; the ruling applies established principles of trademark law to the facts at hand and protects the plaintiff from irreparable harm due to infringement.

    Remidex Pharma Private Limited v. Savita Pharmaceuticals P. Ltd

    Badar Durrez Ahmed, J.:— The question that arises for consideration in the present application under order 39 rules 1 & 2, cpc is whether the plaintiff is entitled to an interim order of injunction, inter alia, restraining the defendant from using the mark “EVIT” in respect of its pharmaceutical products. The plaintiffs case is that the defendant's trademark “EVIT” is deceptively similar to the plaintiff's registered trademark “ZEVIT”.

    2. The plaintiff's trademark “ZEVIT” is registered under Registration No. 452526 on 16.04.1986 in respect of pharmaceuticals, veterinary and sanitary preparations and substances. The original registration was in the name of Eskayef Ltd. The name of that company was changed to Smithkline Beecham Pharmaceuticals (India) Ltd in the year 1994. By a Deed of Assignment dated 19.01.1998, the said registered trademark was assigned by the said Smithkline Beecham Pharmaceuticals (India) Ltd in favour of the plaintiff. It is the plaintiff's case that the trademark “ZEVIT” is an invented word having no dictionary meaning and thus has the highest degree of distinctiveness connoting the plaintiffs goods exclusively. According to the plaintiff, the trademark “ZEVIT” has been used by the plaintiff continuously, regularly and without any hindrance for the last number of years. A sample of the product was annexed as Annexure-B. It indicates that the plaintiff's product “ZEVIT” is a formulation which contains Zinc Sulphate Monohydrate, Vitamins B1, B2, B6, B12, Nicotinamide, Calcium Pantothenate and Vitamin C. Essentially, it is a vitamin formulation.

    3. It is alleged in the plaint that sometime in November, 2002, the plaintiff became aware that the defendant was manufacturing, marketing and selling the vitamin capsules under the trademark “EVIT”.

    4. As per the written statement filed by the defendants, the products marketed by them under the trademark “EVIT” are nothing but vitamin “E” tablets. As per the defendants, the product is a single ingredient vitamin drug. The defendants' drugs are allegedly marketed under the trademark “EVIT” which, according to the defendants, is derived from and adopted to identify the generic name of the drug, namely, ‘Vitamin E’. According to the defendants', the suffix “VIT” is common to the pharmacy trade indicating vitamin preparations.

    5. From these brief facts, it is apparent that the plaintiff is the proprietor of the registered trademark “ZEVIT”. It is also apparent that the plaintiff has also been continuously using the same. The defendants mark “EVIT” is not a registered mark. The defendant has been using this mark in respect of its ‘Vitamin E’ formulations. When this plaint was filed, this court passed an ex parte ad interim order in favour of the plaintiff on 13.02.2003 injuncting the defendants from manufacturing, selling and offering for sale or advertising or directly or indirectly dealing in pharmaceutical preparations under the trademark “EVIT”. This ex parte interim order has continued till date. The plaintiff seeks confirmation of this order and the defendants pray for vacation of the same.

    6. The case of the plaintiff is that the registration of a trademark, by virtue of Section 28 of The Trademarks Act, 1999 (hereinafter referred to as ‘the said Act’) gives to the registered proprietor of the trademark the exclusive right over the trademark in relation to the goods or the services in respect of which the trademark is registered and to obtain relief in respect of infringement of the trademark in the manner provided by the said. Act. Infringement of registered trademarks has been specified under Section 29 of the said Act. It is the plaintiffs case that in view of the provisions of Section 29 of the said Act, infringement is established if it can be shown that the infringing trademark is identical or deceptively similar to the registered trademark in such a manner as to render the use of the mark likely to be taken as being used as a trademark. It is further the case of the plaintiff that in terms of Section 31 of the said Act, registration of a trademark is prima facie evidence of its validity. In support of his contention that the registration of a trademark gives valuable rights to its owner/proprietor, the learned counsel for the plaintiff referred to the following decisions:—

    (i) National Bell Co. v. Metal Goods Manufacturing Co. (P.) Ltd & Anr., AIR 1971 SC 898 : PTC (Suppl)(1) 586 (SC);

    (ii) American Home Products Corporation v. Mac Laboratories Pvt. Ltd & Anr., AIR 1986 SC 137 : 1986 (6) PTC 71 (SC);

    (iii) Durga Dutt Sharma v. N.P Laboratories, AIR 1965 SC 980 : PTC (Suppl)(2) 680 (SC);

    (iv) Avis International Ltd v. Avi Footwear Industries & Anr., AIR 1991 Delhi 22 : PTC (Suppl)(1) 844(DeI).

    7. These decisions need not be examined in detail inasmuch as the position is clear and inescapable that the registration of a trademark gives to the proprietor thereof valuable and exclusive rights as indicated in Section 28 of the said Act. The only question that needs to be considered in the present case is whether the trademark “ZEVIT” and “EVIT” are deceptively similar or not. It has been contended by the learned counsel for the defendant that both the marks can be broken down into two components each. One component is common to both and those are the letters “VIT”. According to the defendants, this portion, i.e, "VIT”, is common to the trade and is of a generic nature inasmuch as it is normally used for vitamin formulations. Therefore, what needs to be compared are the non-generic parts of the marks. The prefix “ZE” as used by the plaintiff and the prefix “E” as used by the defendant. According to the learned counsel for the defendants, these are dissimilar and cannot be confused for one another. Therefore, ignoring the comparison of the generic portions, there is enough dissimilarity to take the case of the defendants mark out of the expression deceptively similar used in Section 29 of the said Act.

    8. For this proposition, the learned counsel for the defendants relied upon the case of F. Hoffimann-La Roche and Co. Ltd. v. Geoffrey Manners and Co. Pvt. Ltd. AIR 1970 SC 2062 : PTC (Suppl)(1) 88 (SC). In that case, the Supreme Court was faced with the comparison of the trademarks ‘DROPOVIT’ and ‘PROTOVIT’. In paragraph 12 of the said decision, the Supreme Court observed that in order to decide whether ‘DROPOVIT’ is deceptively similar to the word ‘PROTOVIT’ each of the two words must, therefore, be taken as a whole word. According to the Supreme Court, each of the two words consists of eight letters, the last three letters are common, and in the uncommon part the first two are consonants, the next is the same vowel ‘o’, the next is a consonant and the fifth is again a common vowel ‘o’. The Supreme Court further observed that the combined effect of these was to produce an alliteration. The Supreme Court also noted that the affidavits of the appellant indicated that the last three letters “VIT” is a well-known common abbreviation used in the pharmaceutical trade to denote Vitamin preparations. In this view, the Supreme Court observed that it is apparent that the terminal syllable “VIT” in the two marks is both descriptive and common to the trade and the Supreme Court further held that if greater regard is paid to the uncommon element in these two words, it is difficult to hold that one will be mistaken for or confused with the other. The Court further held that the letters ‘D’ and T’ in “DROPOVIT” and the corresponding letters ‘P’ and ‘T’ in “PROTOVIT” cannot possibly be slurred over in pronunciation and the words are so dissimilar that there is no reasonable probability of confusion between the words either from the visual or phonetic point of view. The learned counsel for the defendants placed great reliance on this decision of the Supreme Court to contend that the suffix “VIT” is (a) generic in nature and used for vitamin formulations; (b) to be ignored for comparing the marks; (c) that the prefixes “ZE’ and “E” used in the case of the plaintiff's trademark and the defendant's trademark respectively are entirely dissimilar and, therefore, on a comparison of the pre-fixes alone, it cannot be said that the defendant's mark was deceptively similar to the mark used by the plaintiff. A host of other judgments were cited by the counsel for the plaintiff as well as the counsel for the defendants, but I need need examine those judgments as the principles are clear from the aforesaid decision itself. The principles being that the words must be compared as wholes and while comparing the marks, greater regard should be paid to the uncommon element in the two marks and upon such comparison if it is found that the uncommon elements are so dissimilar as cannot be confused with each other, then the conclusion would be that the marks are not deceptively similar. Putting this proposition conversely, it becomes clear that if a comparison of the uncommon elements reveals that there is a likelihood of deception and or similarity and/or confusion, then it can be clearly established that the marks are deceptively similar. Although the learned counsel for the plaintiff submits that the decision in F Hoffimann-La Roche and Co. Ltd. (supra) would not be applicable to the facts of the present case inasmuch as that was a case concerned with a dispute qua registration, whereas the present case is one of infringement of a registered trademark, I feel that the principles with regard to the question of deceptive similarity are quite well laid out in the said decision of the Supreme court and are equally applicable in relation to an action on infringement. But, the decision in F. Hoffimann-La Roche (supra) does not militate against the plaintiff in the facts of the present case.

    9. Comparing the marks “ZEVIT” and “EVIT”, I find that the prefixes “ZE” and “E” are phonetically quite similar. The suffix “VIT” is common to both the marks and is, indeed, identical. The marks taken as a whole, therefore, include identical suffixes and quite similar prefixes, therefore, in my view, the inescapable conclusion is that the mark “EVIT” is deceptively similar to the registered trademark “ZEVIT” of which the plaintiff is the proprietor. The plaintiff, therefore, has been able to establish a good prima facie case and the balance of convenience is also in its favour. If the order prayed for is not granted, it would suffer irreparable harm and injury.

    10. The defendants have raised a plea of delay, however, I am not much concerned with such a plea inasmuch as the present action is more of one of infringement or a registered trademark than one of passing off where such considerations as delay and acquiescence have relevance.

    11. Accordingly, the ex parte ad interim order dated 13.02.2003 is confirmed till the disposal of the suit.

    This application stands disposed of.

    Use AI to get other relevant cases.

    Comments

    Remidex Pharma Private Limited v. Savita Pharmaceuticals P. Ltd
    (Jul 3, 2006)